Next Article in Journal
Levothyroxine Interactions with Food and Dietary Supplements–A Systematic Review
Next Article in Special Issue
Orally Administered NSAIDs—General Characteristics and Usage in the Treatment of Temporomandibular Joint Osteoarthritis—A Narrative Review
Previous Article in Journal
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters
Previous Article in Special Issue
Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis
Review

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

1
St. Catherine Specialty Hospital, 49210 Zabok/10000 Zagreb, Croatia
2
Eberly College of Science, The Pennsylvania State University, University Park, State College, PA 16802, USA
3
The Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, West Haven, CT 06516, USA
4
Medical School, University of Split, 21000 Split, Croatia
5
Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia
6
Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia
7
Medical School, University of Rijeka, 51000 Rijeka, Croatia
8
Medical School REGIOMED, 96450 Coburg, Germany
9
Medical School, University of Mostar, 88000 Mostar, Bosnia and Herzegovina
10
Clinical Hospital “Sveti Duh”, 10000 Zagreb, Croatia
11
Department of Nursing, University North, 48000 Varaždin, Croatia
12
Department of Health Studies, University of Split, 21000 Split, Croatia
13
Clinic for Traumatology, University Hospital “Sisters of Mercy”, 10000 Zagreb, Croatia
14
Department of Orthopaedics and Traumatology, University Hospital Dubrava, 10000 Zagreb, Croatia
15
Aksis Specialty Hospital, 10000 Zagreb, Croatia
16
General Hospital Karlovac, 47000 Karlovac, Croatia
*
Author to whom correspondence should be addressed.
Academic Editor: Siyoung Yang
Pharmaceuticals 2021, 14(3), 205; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14030205
Received: 11 February 2021 / Revised: 24 February 2021 / Accepted: 26 February 2021 / Published: 2 March 2021
(This article belongs to the Special Issue Drug and Therapy for Osteoarthritis (OA))
Osteoarthritis is the most common musculoskeletal progressive disease, with the knee as the most commonly affected joint in the human body. While several new medications are still under research, many symptomatic therapy options, such as analgesics (opioid and non-opioid), nonsteroid anti-inflammatory drugs, symptomatic slow-acting drugs in osteoarthritis, and preparations for topical administration, are being used, with a diverse clinical response and inconsistent conclusions across various professional societies guidelines. The concept of pharmacogenomic-guided therapy, which lies on principles of the right medication for the right patient in the right dose at the right time, can significantly increase the patient’s response to symptom relief therapy in knee osteoarthritis. Corticosteroid intra-articular injections and hyaluronic acid injections provoke numerous discussions and disagreements among different guidelines, even though they are currently used in daily clinical practice. Biological options, such as platelet-rich plasma and mesenchymal stem cell injections, have shown good results in the treatment of osteoarthritis symptoms, greatly increasing the patient’s quality of life, especially when combined with other therapeutic options. Non-inclusion of the latter therapies in the guidelines, and their inconsistent stance on numerous therapy options, requires larger and well-designed studies to examine the true effects of these therapies and update the existing guidelines. View Full-Text
Keywords: knee osteoarthritis; guidelines; drug therapy; pharmacogenomics; intra-articular injections; mesenchymal stem cells knee osteoarthritis; guidelines; drug therapy; pharmacogenomics; intra-articular injections; mesenchymal stem cells
MDPI and ACS Style

Primorac, D.; Molnar, V.; Matišić, V.; Hudetz, D.; Jeleč, Ž.; Rod, E.; Čukelj, F.; Vidović, D.; Vrdoljak, T.; Dobričić, B.; Antičević, D.; Smolić, M.; Miškulin, M.; Ćaćić, D.; Borić, I. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines. Pharmaceuticals 2021, 14, 205. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14030205

AMA Style

Primorac D, Molnar V, Matišić V, Hudetz D, Jeleč Ž, Rod E, Čukelj F, Vidović D, Vrdoljak T, Dobričić B, Antičević D, Smolić M, Miškulin M, Ćaćić D, Borić I. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines. Pharmaceuticals. 2021; 14(3):205. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14030205

Chicago/Turabian Style

Primorac, Dragan, Vilim Molnar, Vid Matišić, Damir Hudetz, Željko Jeleč, Eduard Rod, Fabijan Čukelj, Dinko Vidović, Trpimir Vrdoljak, Borut Dobričić, Darko Antičević, Martina Smolić, Mladen Miškulin, Damir Ćaćić, and Igor Borić. 2021. "Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines" Pharmaceuticals 14, no. 3: 205. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14030205

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop